{"id":"W4200183746","doi":"10.1016/j.dsx.2021.102382","title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial","year":2021,"lang":"en","type":"review","venue":"Diabetes & Metabolic Syndrome Clinical Research & Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Merck Sharp and Dohme; Novo Nordisk; University of Glasgow; British Heart Foundation; Sanofi; Kowa Company; Amgen; Boehringer Ingelheim; Novartis; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Abbott Laboratories","keywords":"Glucagon-like peptide 1 receptor; Exenatide; Agonist; Medicine; Mace; Internal medicine; Receptor; Clinical trial; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Pharmacology; Endocrinology; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0309265,0.002063116,0.03990693,0.001288447,0.0003224919,0.0004479304,0.001268806,0.0005612366,0.0003138438],"category_scores_gemma":[0.003928116,0.0008570972,0.01693973,0.007410071,0.001254854,0.0002811404,0.0008577256,0.002597143,0.0001166804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000223958,"about_ca_system_score_gemma":0.0008013294,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000177776,"about_ca_topic_score_gemma":0.0001634427,"domain_scores_codex":[0.9718414,0.01367361,0.003655692,0.003353221,0.005410348,0.00206575],"domain_scores_gemma":[0.9854853,0.003614981,0.001061653,0.007784955,0.001106868,0.0009462066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002209894,0.00186569,0.2563444,0.003499383,0.5710535,0.0001372296,0.00002509673,0.000003144825,9.942862e-10,0.000007974485,0.0001826721,0.1666599],"study_design_scores_gemma":[0.01044169,0.002188521,0.08113919,0.001137888,0.4231559,8.724217e-7,0.00001888324,6.783995e-7,1.90121e-8,0.000001112053,0.4813796,0.0005356352],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0923088,0.8849657,0.000002451736,0.0001124073,0.0001957552,0.02216478,0.0001167527,0.00005768147,0.00007562931],"genre_scores_gemma":[0.001951779,0.9861168,0.0004872856,0.0001853565,0.0001528479,0.009244801,0.0009070222,0.0002603562,0.0006938041],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4811969,"threshold_uncertainty_score":0.9997039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2385434492425108,"score_gpt":0.4451228867651156,"score_spread":0.2065794375226049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}